Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection

Hepatology

Volumn 57, Issue 3, 2013, Pages 1262-1271

  Polyak, Stephen J ^a   Ferenci, Peter ^b   Pawlotsky, Jean Michel ^c,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d INSERM U955   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIOXIDANT; CONIFERYL ALCOHOL; GREEN TEA EXTRACT; ISOSILYBIN A; ISOSILYBIN B; ISOSILYCHRISTIN; LEGALON SIL; MEDIHERB; MULTIVITAMIN; PEGINTERFERON ALPHA; PLACEBO; REALSIL; RIBAVIRIN; SILIBININ DIHEMISUCCINATE; SILIBININ PHOSPHATIDYLCHOLINE COMPLEX; SILICRISTIN; SILIDIANIN; SILYBIN A; SILYBIN B; SILYMARIN; TAXIFOLIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE HEPATITIS; ACUTE LIVER FAILURE; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ANTIVIRAL ACTIVITY; ARTHRALGIA; CANCER INHIBITION; CHOLESTATIC HEPATITIS; CHRONIC HEPATITIS; CLINICAL TRIAL (TOPIC); COLLAPSE; DIARRHEA; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; END STAGE LIVER DISEASE; EPIGASTRIC DISCOMFORT; GRAFT INFECTION; HEPATITIS C; HUMAN; JAUNDICE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER PROTECTION; MUSHROOM POISONING; NAUSEA; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REINFECTION; REVIEW; URTICARIA; VIRUS HEPATITIS; VIRUS RESISTANCE; VOMITING;

EID: 84874491262     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26179     Document Type: Review

References (79)

1. NCCAM. Hepatitis C and complementary and alternative medicine: 2003 update. In: Research Report: National Center for Complementary and Alternative Medicine; 2003. p 2-20.
2. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. HEPATOLOGY 2008; 47: 605-612.
3. Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, Wright EC, et al. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol 2002; 97: 2391-2397.
4. Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized silymarin. Gastroenterology 2007; 132: 1925-1936.
5. Freedman ND, Curto TM, Morishima C, Seeff LB, Goodman ZD, Wright EC, et al., the HALT-C Trial Group. Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Aliment Pharmacol Ther 2011; 33: 127-137.
6. Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol 2010; 50: 434-449.
7. Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA 2012; 308: 274-282.
8. Wagner H, Horhammer L, Munster R. [On the chemistry of silymarin (silybin), the active principle of the fruits from Silybum marianum (L.) Gaertn. (Carduus marianus L.).] Arzneimittelforschung 1968; 18: 688-696.
9. Wagner H, Horhammer L, Seitz M. [Chemical evaluation of a silymarin-containing flavonoid concentrate from Silybum marianum (L.) Gaertn.] Arzneimittelforschung 1968; 18: 696-698.
10. Vogel G, Temme I. [Curative antagonism of phalloidin induced liver damage with silymarin as a model of an antihepatotoxic therapy.] Arzneimittelforschung 1969; 19: 613-615.
11. Schriewer H, Lohmann J, Rauen HM. [The effect of silybin-dihemisuccinate on regulation disorders in phospholipid metabolism in acute galactosamine intoxication in the rat.] Arzneimittelforschung 1975; 25: 1582-1585.
12. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 1561-1567.
13. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett 2008; 269: 352-362.
14. Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, et al. Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci U S A 2010; 107: 5995-5999.
15. Tager M, Dietzmann J, Thiel U, Hinrich Neumann K, Ansorge S. Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the flavonoids silibinin and silymarin. Free Radic Res 2001; 34: 137-151.
16. Lu P, Mamiya T, Lu LL, Mouri A, Zou L, Nagai T, et al. Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. Br J Pharmacol 2009; 157: 1270-1277.
17. Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 2010; 29: 447-463.
18. Singh RP, Agarwal R. Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 2006; 45: 436-442.
19. Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 2007; 6: 110-119.
20. Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC, et al. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res 2005; 65: 4448-4457.
21. Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 2008; 36: 65-72.
22. Weyhenmeyer R, Mascher H, Birkmayer J. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int J Clin Pharmacol Ther Toxicol 1992; 30: 134-138.
23. Rickling B, Hans B, Kramarczyk R, Krumbiegel G, Weyhenmeyer R. Two high-performance liquid chromatographic assays for the determination of free and total silibinin diastereomers in plasma using column switching with electrochemical detection and reversed-phase chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 1995; 670: 267-277.
24. Gatti G, Perucca E. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. Int J Clin Pharmacol Ther 1994; 32: 614-617.
25. Lorenz D, Lucker PW, Mennicke WH, Wetzelsberger N. Pharmacokinetic studies with silymarin in human serum and bile. Methods Find Exp Clin Pharmacol 1984; 6: 655-661.
26. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001; 61: 2035-2063.
27. Schrieber SJ, Hawke RL, Wen Z, Smith PC, Reddy KR, Wahed AS, et al. Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos 2011; 39: 2182-2190.
28. Schrieber SJ, Wen Z, Vourvahis M, Smith PC, Fried MW, Kashuba AD, et al. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos 2008; 36: 1909-1916.
29. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7: 273-282.
30. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004; 36: 57-104.
31. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007; 25: 139-146.
32. Toxicology and carcinogenesis studies of milk thistle extract (CAS No. 84604-20-6) in F344/N rats and B6C3F1 mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 2011: 1-177.
33. Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 1993; 31: 456-460.
34. Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997; 26: 871-879.
35. Adverse Drug Reactions Advisory Committee. An adverse reaction to the herbal medication milk thistle (Silybum marianum). Med J Aust 1999; 170: 218-219.
36. Pares A, Planas R, Torres M, Caballeria J, Viver JM, Acero D, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998; 28: 615-621.
37. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000; 28: 1270-1273.
38. Rauen HM, Schriewer H, Tegtbauer U, Lasana JE. [Silymarin prevents peroxidation of lipids in carbon tetrachloride-induced liver damage.] Experientia 1973; 29: 1372.
39. Wu CG, Chamuleau RA, Bosch KS, Frederiks WM. Protective effect of silymarin on rat liver injury induced by ischemia. Virchows Arch B Cell Pathol Incl Mol Pathol 1993; 64: 259-263.
40. Trost W, Halbach G. Anti-phalloidine and anti-alpha-amanitine action of silybin in comparison with compounds similar to structural parts of silybin. Experientia 1978; 34: 1051-1052.
41. Campos R, Garrido A, Guerra R, Valenzuela A. Acetaminophen hepatotoxicity in rats is attenuated by silybin dihemisuccinate. Prog Clin Biol Res 1988; 280: 375-378.
42. Valenzuela A, Lagos C, Schmidt K, Videla LA. Silymarin protection against hepatic lipid peroxidation induced by acute ethanol intoxication in the rat. Biochem Pharmacol 1985; 34: 2209-2212.
43. Patel N, Joseph C, Corcoran GB, Ray SD. Silymarin modulates doxorubicin-induced oxidative stress, Bcl-xL and p53 expression while preventing apoptotic and necrotic cell death in the liver. Toxicol Appl Pharmacol 2010; 245: 143-152.
44. Kiesewetter E, Leodolter I, Thaler H. [Results of two double-blind studies on the effect of silymarine in chronic hepatitis (author's transl).] Leber Magen Darm 1977; 7: 318-323.
45. Marcelli R, Bizzoni P, Conte D, Lisena MO, Lampertico M, Marena C, et al. Randomized controlled study of the efficacy and tolerability of a short course of IdB 1016 in the treatment of chronic persistent hepatitis. Eur Bull Drug Res 1992; 1: 131-135.
46. Gordon A, Hobbs DA, Bowden DS, Bailey MJ, Mitchell J, Francis AJ, et al. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 21: 275-280.
47. Tanamly MD, Tadros F, Labeeb S, Makld H, Shehata M, Mikhail N, et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis 2004; 36: 752-759.
48. Melhem A, Stern M, Shibolet O, Israeli E, Ackerman Z, Pappo O, et al. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin Gastroenterol 2005; 39: 737-742.
49. Huber R, Futter I, Ludtke R. Oral silymarin for chronic hepatitis C - a retrospective analysis comparing three dose regimens. Eur J Med Res 2005; 10: 68-70.
50. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB. Anticancer potential of silymarin: from bench to bed side. Anticancer Res 2006; 26: 4457-4498.
51. Gazak R, Walterova D, Kren V. Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem 2007; 14: 315-338.
52. Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, et al. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology 2010; 138: 671-681, 681 e671-672.
53. Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. HEPATOLOGY 2010; 51: 1912-1921.
54. Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 2010; 138: 1112-1122.
55. Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pecheur EI, et al. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One 2011; 6: e16464.
56. Saller R, Brignoli R, Melzer J, Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed 2008; 15: 9-20.
57. Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Del Vecchio Blanco C, et al. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut 2006; 55: 901-902.
58. Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med 2012; 52: 1658-1665.
59. Rutter K, Scherzer TM, Beinhardt S, Kerschner H, Stattermayer AF, Hofer H, et al. Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy. Antivir Ther 2011; 16: 1327-1333.
60. Biermer M, Schlosser B, Fulop B, van Bommel F, Brodzinski A, Heyne R, et al. High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy. J Viral Hepat 2012; 19: 547-553.
61. Klein AS, Hart J, Brems JJ, Goldstein L, Lewin K, Busuttil RW. Amanita poisoning: treatment and the role of liver transplantation. Am J Med 1989; 86: 187-193.
62. Pinson CW, Daya MR, Benner KG, Norton RL, Deveney KE, Ascher NL, et al. Liver transplantation for severe Amanita phalloides mushroom poisoning. Am J Surg 1990; 159: 493-499.
63. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol 2010; 52: 951-952.
64. Beinhardt S, Rasoul-Rockenschaub S, Maieron A, Hofer PF. Intravenous silibinin-therapy in patients with chronic hepatitis C in the transplant setting. J Hepatol 2012; 56: S77.
65. Aghemo A, Bhoori S, De Nicola S, Mazzaferro V. Failure of intravenous silibinin monotherapy to prevent hepatitis C genotype 2A liver graft reinfection. Hepat Mon 2012; 12: 411-414.
66. Eurich D, Bahra M, Berg T, Boas-Knoop S, Biermer M, Neuhaus R, et al. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy. Exp Clin Transplant 2011; 9: 1-6.
67. Mariño Z, Crespo G, D'Amato M, Brambilla N, Giacovelli G, Rovati L, Costa J, Navasa M, Forns X. Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. J Hepatol 2013; 58: 415-420.
68. Saller R, Melzer J, Reichling J, Brignoli R, Meier R. An updated systematic review of the pharmacology of silymarin. Forsch Komplementmed 2007; 14: 70-80.
69. Koller F. The interaction of silibinin with hepatocellular organic anion transporters. Zürich: Swiss Federal Institute of Technology; 2011.
70. Payer BA, Reiberger T, Rutter K, Beinhardt S, Staettermayer AF, Peck-Radosavljevic M, et al. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. J Clin Virol 2010; 49: 131-133.
71. McClure J, Lovelace ES, Elahi S, Maurice NJ, Wagoner J, Dragavon J, et al. Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation. PLoS One 2012; 7: e41832.
72. Egger D, Wolk B, Gosert R, Bianchi L, Blum HE, Moradpour D, et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002; 76: 5974-5984.
73. Bunout D, Hirsch S, Petermann M, de la Maza MP, Silva G, Kelly M, et al. [Controlled study of the effect of silymarin on alcoholic liver disease.] Rev Med Chil 1992; 120: 1370-1375.
74. El-Kamary SS, Shardell MD, Abdel-Hamid M, Ismail S, El-Ateek M, Metwally M, et al. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine 2009; 16: 391-400.
75. Feher J, Deak G, Muzes G, Lang I, Niederland V, Nekam K, Karteszi M. [Liver-protective action of silymarin therapy in chronic alcoholic liver diseases.] Orv Hetil 1989; 130: 2723-2727.
76. Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9: 105-113.
77. Lang I, Nekam K, Deak G, Muzes G, Gonzales-Cabello R, Gergely P, et al. Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers. Ital J Gastroenterol 1990; 22: 283-287.
78. Magliulo E, Gagliardi B, Fiori GP. [Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres (author's transl).] Med Klin 1978; 73: 1060-1065.
79. Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol 1982; 17: 517-521.